

13 May 2021

**Diaceutics PLC**

("Diaceutics" or "the Company")

**LGC SeraCare Partnership**

*Partnership expands diagnostic commercialisation solutions enabled by global DXRX platform*

[Diaceutics PLC](#), (AIM: DXRX), today announces a new partnership with LGC SeraCare ("SeraCare"), the US-based manufacturer of diagnostic test reference standard controls. The partnership sees LGC SeraCare join the Diaceutics DXRX Network, the world's first end-to-end digital solution for the development and commercialisation of precision medicine diagnostics, expanding the range of test standardisation solutions available via the platform.

DXRX has been designed to accelerate diagnostic testing accuracy to ensure that precision medicines are correctly prescribed to eligible patients at the right time in the treatment journey, securing the best possible outcomes. LGC SeraCare joins a growing network of industry leaders in precision medicine diagnostics who use the platform's technology to collaborate digitally to enable seamless diagnostic testing for precision medicines, ahead of market launch.

Existing laboratory testing solutions partners on the DXRX platform include Targos Molecular Pathology, Histocyte Laboratories, CPQA-ACQP, EMQN CIC, NordiQC, UKNEQAS and Alva10 Dx. This new partnership introduces additional types of test reference materials and technologies to the platform including Seraseq™ FFPE Tumor Fusion RNA Reference Material v4 and Seraseq™ FFPE NTRK Fusion RNA Reference Material, available in 132 countries.

By providing these critical technologies to the DXRX platform, both LGC SeraCare and Diaceutics will be able to advance their goal of enabling greater adoption of precision medicine by enabling all laboratories to provide consistently high quality testing using reference material to validate their test system, faster.

**Alpa Shah, Senior Director Sales, Clinical Genomics LGC SeraCare commented on the partnership:**

*"As a provider of innovative technologies that leverage our deep experience and unique perspective to enable the promise of precision medicine, we are delighted to be joining what is a network of true innovators in the industry. Our unwavering commitment to serve and empower clinical and research laboratories, as well as in vitro diagnostics developers is aligned with DXRX as a platform solution which places the laboratory at the centre of a precision medicine network and enables the diagnostic industry to extract more value from Precision Medicine. We look forward to the continued expansion of our offering via the platform and the business development opportunities it brings to SeraCare."*

**DXRX Network Advisor, Kenneth J. Bloom, Chief Medical Officer of Advanced Pathology and Genomic Services, Konica Minolta Precision Medicine commented,**

*"As the post-covid testing landscape emerges with new complexity, it is now more critical than ever that pharma are collaborating digitally with key stakeholders in the testing supply chain to guarantee diagnostic testing accuracy. It is fantastic to see this collaboration which is an important step in getting every patient the treatment they deserve."*

**Enquiries:**

**Diaceutics PLC**

Peter Keeling, Chief Executive Officer  
Philip White, Chief Financial Officer

[www.diaceutics.com](http://www.diaceutics.com)  
via Alma PR

**Cenkos Securities plc (Nominated adviser and broker)**

Callum Davidson / Giles Balleny  
Michael Johnson (Sales)

+44 (0)207 397 8900

**Alma PR**

Caroline Forde  
Robyn Fisher  
Kieran Breheny

Tel: +44 (0)20 3405 0205  
or [diaceutics@almapr.co.uk](mailto:diaceutics@almapr.co.uk)

**About LGC SeraCare**

Trusted partner to the diagnostic testing industry, LGC SeraCare is a leading partner and supplier of [diagnostic quality controls](#), [biological materials](#), and [reagents](#) to in vitro diagnostics developers, clinical laboratories, and life science researchers worldwide. The company provides access to data-rich natural and biosynthetic specimens to accelerate assay development and validation, a consistent and stable supply of high-quality biologic raw materials and other customized IVD reagents, and platform-specific controls, panels, and data to challenge assays and ensure diagnostic accuracy.

#### **About Diaceutics**

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - our Proprietary Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. The Company, listed on the AIM Market of the London Stock Exchange, has created commercially useful data sets for every precision medicine that has come to market. We have built the world's largest repository of diagnostic testing data with a growing network of 2,500 laboratories in 51 countries. [www.diaceutics.com](http://www.diaceutics.com)

#### **About DXRX - The Diagnostic Network®**

DXRX is Diaceutics' proprietary diagnostic network for precision medicine. DXRX is an end-to-end solution for the development and commercialisation of Precision Medicine diagnostics. The platform enables a vibrant marketplace where all stakeholders in Precision Medicine come to find trusted partners and collaborations in a secure, standardised way. DXRX provides access to a pipeline of global diagnostic testing data on one secure platform.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAEAKSAFADFEFA